NCT00737126

The Effect of Folic Acid Administration in the Progression of Microalbuminuria

Folic Acid Administration Reduces the Progression of Microalbuminuria

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Hospital Universitario Dr. Jose E. Gonzalez · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The development of diabetic nephropathy has been linked to several genetic polymorphisms, including those related with homocysteine metabolism such as the methylenetetrahydrofolate reductase (MTHFR)and the cystathionine-beta-synthase genes. Such alterations are associated with hyperhomocysteinemia, which is a known independent risk factor for the development of endothelial dysfunction and cardiovascular disease. In the Mexican population there is a high prevalence of the C677T MTHFR mutation. The investigators performed this study to evaluate the prevalence of this polymorphism in type 2 diabetic patients with diabetic nephropathy compared with type 2 diabetic patients without nephropathy, besides evaluating the relationship of hyperhomocysteinemia with endothelial dysfunction and microalbuminuria before and after the administration of folic acid. We proposed that the endothelial dysfunction caused by the hyperhomocysteinemia could be reversed after the administration of folic acid.

Conditions

• Diabetic Nephropathies
• Hyperhomocysteinemia

Interventions

Type	Name	Description
DRUG	Folic acid	Administration of a daily tablet containing 5 mg of folic acid for 4 months.
DRUG	Placebo	Administration of an oral placebo pill

Timeline

• Start date: 2004-01-01
• Primary completion: 2005-12-01
• Completion: 2005-12-01
• First posted: 2008-08-18
• Last updated: 2008-08-19

Locations

1 site across 1 country: Mexico